Clioquinol induces S-phase cell cycle arrest through the elevation of the calcium level in human neurotypic SH-SY5Y cells.
Antineoplastic Agents
/ pharmacology
Autophagy
/ drug effects
Calcium
/ analysis
Cell Line, Tumor
Chelating Agents
/ pharmacology
Clioquinol
/ pharmacology
Cyclin-Dependent Kinase 2
/ metabolism
Cyclin-Dependent Kinase Inhibitor p21
/ metabolism
Cyclin-Dependent Kinase Inhibitor p27
/ metabolism
Humans
Iron
/ analysis
S Phase Cell Cycle Checkpoints
/ drug effects
Zinc
/ analysis
Journal
Metallomics : integrated biometal science
ISSN: 1756-591X
Titre abrégé: Metallomics
Pays: England
ID NLM: 101478346
Informations de publication
Date de publication:
01 02 2020
01 02 2020
Historique:
pubmed:
23
11
2019
medline:
13
1
2021
entrez:
23
11
2019
Statut:
ppublish
Résumé
Clioquinol is recently considered to be the most promising drug for treating cancer and neurodegenerative diseases. However, its mode of action varies from different disease models. In this study, we found that clioquinol inhibited cell growth in human neurotypic SHSY-5Y cells, which was attributed to both S-phase cell-cycle arrest and autophagic cell death. Clioquinol increased the intracellular contents of iron and zinc as well as calcium as measured by ICP-AES. Staining of Fluo-3 confirmed an increase in the level of calcium. Analysis of the metal-binding ability of clioquinol showed that it was not a chelating agent of calcium ions and the elevation of intracellular calcium content is not achieved by clioquinol as an ionophore. CaCl
Substances chimiques
Antineoplastic Agents
0
Chelating Agents
0
Cyclin-Dependent Kinase Inhibitor p21
0
Cyclin-Dependent Kinase Inhibitor p27
147604-94-2
Clioquinol
7BHQ856EJ5
Iron
E1UOL152H7
CDK2 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 2
EC 2.7.11.22
Zinc
J41CSQ7QDS
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM